Global Tuberculosis Report 2024

Introduction to the Global Tuberculosis Report 2024

The WHO Global Tuberculosis Report 2024 provides a crucial update on the global and national fight against Tuberculosis (TB). This report highlights key trends, challenges, and progress in TB elimination efforts worldwide.

India's performance is a significant focus, showcasing both achievements and areas requiring intensified efforts to meet elimination targets.

India's Progress in TB Incidence Decline

According to the WHO Global Tuberculosis Report 2024, India has demonstrated a remarkable decline in TB incidence. From 2015 to 2023, India achieved a 17.7% reduction in TB cases.

Global TB Incidence Trends in 2023

The report reveals a concerning increase in new TB cases globally. In 2023, approximately 8.2 million new TB cases were reported, a rise from 7.5 million in 2022.

Despite the rise in incidence, there was a slight decrease in TB-related deaths. An estimated 1.25 million TB deaths were recorded in 2023, a marginal reduction from 1.32 million in 2022.

Demographics of Global TB Cases

The burden of TB is disproportionately concentrated in certain regions and populations. Low- and middle-income countries (LMICs) bear the brunt, accounting for 87% of the global TB burden.

The report also details the distribution of TB cases by gender and age: 55% of cases occurred in men, 33% in women, and 12% in children and young adolescents.

India's Specific TB Scenario in 2023

In 2023, India recorded an estimated 27 lakh TB cases. Out of these, 25.1 lakh individuals were successfully diagnosed and initiated treatment, reflecting improved case detection.

Treatment coverage in India significantly improved, rising from 72% in 2015 to 89% in 2023. This expansion has been crucial in reducing the number of undiagnosed or untreated cases.

WHO End TB Strategy Goals and India's Position

The WHO's End TB Strategy sets ambitious post-2015 milestones: a 75% reduction in TB deaths and a 50% reduction in incidence from 2015 levels by 2025.

Current progress suggests India will not achieve the specific targets of reducing TB deaths to 7 per 1,00,000 population and incidence to 118.5 per 1,00,000 population by 2025.

Understanding Tuberculosis (TB)

Tuberculosis (TB) is a serious infectious disease primarily caused by the bacterium Mycobacterium tuberculosis. It most commonly affects the lungs, but can also impact other parts of the body.

Symptoms: Common symptoms include a persistent cough with sputum (sometimes blood), chest pains, general weakness, unexplained weight loss, persistent fever, and drenching night sweats.

Treatment: TB is both a treatable and curable disease. The standard treatment involves a 6-month course of antimicrobial drugs. This treatment is typically provided with supervision and support from a health worker or trained volunteer to ensure adherence.

Drug-Resistant Tuberculosis

Over decades, strains of TB bacteria have developed resistance to one or more anti-TB medicines. This poses a significant challenge to global TB control.

Extensively drug-resistant TB (XDR-TB): This is a more severe form of MDR-TB. It is caused by bacteria that are resistant not only to first-line drugs but also to the most effective second-line anti-TB drugs. XDR-TB often leaves patients with very limited or no further treatment options, making it extremely challenging to cure.

Initiatives Mentioned in Source Material (Note: These are Polio-related)

The provided source material, within the context of the Global Tuberculosis Report, also listed several initiatives related to Polio Eradication. While not directly pertaining to TB, they highlight India's broader public health efforts.

• Pulse Polio Programme
• Intensified Mission Indradhanush 2.0
• Polio Eradication and Endgame Strategic Plan 2013-2018
• World Polio Day (24th October)
• Global Polio Eradication Initiative (GPEI)